Hyaluronic acid–British anti-Lewisite as a safer chelation therapy for the treatment of arthroplasty-related metallosis

<p dir="ltr">This journal contribution is published Open Access by the publisher. Follow the DOI link to retrieve a copy of the full text. </p><p dir="ltr">We acknowledge support from Carnegie Mellon University’s CTTEC Gap Funds (S.A.S.), an Innovation Fellowship (B.D.H./S.A.S.), and start-up grant (S.A.S.) and the support from University of Connecticut Health through NIH DP1AR068147 and NIH T32AR079114 grants. Other supports were the NSF I-Corp program (S.A.S.) and the Pennsylvania Infrastructure Technology Alliance (S.A.S.)’ NSF (CHE-0130903, CHE-1039870, and CHE-1726525). We thank Zoe Wright for creating the artistic rendering of the mouse in Fig. 1.,C.C.U., S.J.S., S.L., S.S., J.E., B.D.H., L.S.N., S.A.S., and C.T.L. designed research; C.C.U., S.J.S., S.L., S.S., J.E., H.-M.K., B.D.H., A.M.A., M.E.W., S.A.S., and C.T.L. performed research; C.C.U., S.J.S., S.L., S.S., J.E., B.D.H., A.M.A., M.E.W., S.A.S., and C.T.L. contributed new reagents/analytic tools; C.C.U., S.J.S., S.L., H.-M.K., B.D.H., L.S.N., S.A.S., and C.T.L. analyzed data; and C.C.U., S.J.S., S.L., S.S., and C.T.L. wrote the paper.,S.J.S., B.D.H., S.A.S., and C.T.L. are part of BioBind INC, a startup pharmaceutical manufacturing company driven to commercialize BAL-HA as one of the Biobinder technology. The ownership of Biobind is between authors (S.J.S., B.D.H., S.A.S., and C.T.L.) and the company has a value of over $5000. The authors disclose the following patent filings: S.J.S., B.D.H., A.M.A., S.A.S., and C.T.L., Chelator functionalized glycosaminoglycans-patent. US Patent Application Publication, Pub. No. US 2020/0062869 A1 2020.</p>